Detalhe da pesquisa
1.
Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity.
Am J Hum Genet
; 104(6): 1158-1168, 2019 06 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31155283
2.
Virtual screening identifies a PIN1 inhibitor with possible antiovarian cancer effects.
J Cell Physiol
; 234(9): 15708-15716, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30697729
3.
Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
Drug Resist Updat
; 39: 18-40, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30075835
4.
Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk.
Biomed Pharmacother
; 154: 113644, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36063648
5.
The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines.
Cancer Drug Resist
; 2(1): 116-130, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-35582139
6.
Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC).
Cells
; 8(10)2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31581548
7.
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice.
Clin Pharmacol Ther
; 105(4): 994-1002, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30339275
8.
Immunogenetics of prostate cancer: a still unexplored field of study.
Pharmacogenomics
; 19(3): 263-283, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29325503